This article is more than 5 years old. Information may no longer be current.

IND application accepted for CRISPR genome editing treatment for LCA10

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has accepted an investigational new drug application for Editas Medicine’s experimental CRISPR genome editing medicine for the treatment of Leber congenital amaurosis type 10, the company announced in a press release.

EDIT-101 is administered as a subretinal injection to deliver gene editing machinery to photoreceptor cells.

“The FDA’s acceptance of our IND for EDIT-101 is a significant moment in the field of genome editing, and importantly, a critical milestone for patients, as we are now one step closer to a treatment for LCA10,” Editas President and CEO Katrine Bosley said in the release.

The acceptance sparks a $25 million milestone payment to Editas from Allergan as part of a partnership between to two companies to develop experimental ocular medicines.

A phase 1/2 open-label, dose-escalation study of EDIT-101 is planned to evaluate its safety, tolerability and efficacy.